Live
Oncotype DX Breast Cancer Testing
£272,700
services
Contract Details
- Tender Value
- £272,700
- Stage
- Live
- Published
- Awarded
Timeline
Awarded
Disclosed
Start
End
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Related Contracts
From This Buyer
- Patient Experience AI
£140,000 ·
- Saw Blades
£94,491 ·
- Cancer Chemocare System CIS Oncology
£29,953 ·
- Learning Management System
£128,963 ·
From This Supplier
In This Category
- Taxi and MPV (1-8 seats) Passenger Assistant - Taxi and MPV (1-8 seats) Passenger Assistant
£91,057 ·
- QLT354 2026-08-26 (0900) Leiston - Roman Hill Primary School, Lowestoft (4 seats and a PA) - AWARD
£0 ·
- QBR087 2026-08-26 (0900) Lowestoft / Worlingham - The Woodview Project, Worlingham (6 seats and a PA) - AWARD
£0 ·
- QOC940 2026-08-25 (0900) Lowestoft - Ness Point School, Gt Yarmouth (4 seats) - AWARD
£0 ·
Ref: be83749f-55db-4eb4-b59b-40aa06ac75c4-886769 · Sourced from Contracts Finder
View source notice